Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness
CADTH
Record ID 32012000708
English
Authors' recommendations:
Tiotropium appears to help improve objective lung function test measures, reduce the proportion of patients with =1 exacerbation, and improve COPD-related symptoms. There were conflicting results between the two included reports regarding a reduction in frequency of exacerbations. The use of tiotropium did not demonstrate a survival benefit.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/aug-2012/RC0384%20Tiotropium%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Scopolamine Derivatives
- Ipratropium
- Pulmonary Disease, Chronic Obstructive
- Tiotropium Bromide
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.